An observational study in Ovarian Cancer, Ovarian Cyst Benign and Borderline Ovarian Cancer, sponsored by ZIWIG. Active, not recruiting at 21 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by ZIWIG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 291 studies in Ovarian Neoplasms with a site in France — 63 open to participants now, 103 under way, 25 of them phase 3. Ovarian Neoplasms · France.
Among the 291 studies in Ovarian Neoplasms with a site in France, this one is the 14th largest by enrollment of the 44 observational ones that give a count, is one of 15 that started in 2022, is one of 44 observational ones, reaches primary completion later than 16 of the 102 other live ones, and was the 229th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →63 of the 291 studies in Ovarian Neoplasms with a site in France are open now. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 15–49
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in France, United States, Argentina and 19 more countries
Ages 18+ · Women only
Genmab · Sites in France, United States, Australia and 13 more countries
Ages 18+ · Women only
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Boehringer Ingelheim · Sites in France, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 92 · Phase 3 65 · Phase 4 2
First in 1995; this study’s year is marked. 15 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 746 is above the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 201 across the 245 interventional studies, 232 across the 44 observational. Of the 171 that completed or were terminated, 50 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 291 have an industry lead sponsor. The 10 most frequent:
ZIWIG is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
ZIWIG has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
30 of the studies in Ovarian Neoplasms with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
Add all 30 to your calendar (.ics) → With an account.
Among the 291 studies in Ovarian Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
OVAmiARN is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in 8 obstetrics and gynecology departments in France; in order to describe the evolution of salivary miRNA expression between the pre-operative and post-therapy visits according to the type of mass. In time, the clinical application will be to significantly reduce the time to diagnosis and improve the care pathway for ovarian adnexal mass.
The study population consists of patients with an ovarian adnexal mass diagnosed by clinical examination and imaging (pelvic ultrasound and/or MRI) and requiring surgical management in routine care.
The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the HAS, CNGOF.
In this study, the management and follow-up of patients :
The study population consists of patients with an ovarian adnexal mass diagnosed by clinical examination and imaging (pelvic ultrasound and/or MRI and/or blood tumour markers) and requiring surgical management in routine care.
The patients concerned by the study already benefit from a surgical management in different gynecology-obstetrics/gynecological oncology departments in France, Canada and Tunisia, as well as from a validation of the therapeutic indications in accordance with the national practices in force.
The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations (imaging and/or blood tumour markers) necessary according to the context which are carried out according to the national and/or international recommendations in force.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 patients
Other: Salivary samples
200 patients
Other: Salivary samples
60 patients
Other: Salivary samples
For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care): * During the inclusion visit, * At the postoperative visit, * At the 6-month follow-up visit For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care): * At the inclusion visit, * During the postoperative visit, * At the follow-up visits (6 months post-surgery and then every 6 months until 24 months) For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care): * At the inclusion visit, * During the postoperative visit, * During pre- and post-chemotherapy visits (before and after each cycle) * During follow-up visits (every 4 months until 24 months)
Area under the curve (AUC) of the Receiver Operating Curve (ROC)
Identifying a signature of ovarian cancer diagnosis by analysis of coding and non-coding RNAs in the saliva of subjects
Time frame: Through the end of study inclusions, an average of 6 months
Ran from May 2022 to primary completion in Apr 2025, 35 months.
Of 52 industry-sponsored observational studies under Ovarian Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 71. This study's 35 months is below that.
Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ZIWIG